In parallel, recent advancements in diagnosing Alzheimer's disease have turned towards using several accessible blood tests that measure biomarkers such as amyloid-β and tau pathology, both recognized features of the disease, in addition to assessing neurodegeneration [97, 107] In a retrospective study conducted by Benedet et al. [98], an interesting correlation between plasma NfL levels and magnetic resonance imaging measurements of gray and white matter levels in the Alzheimer's Disease Neuroimaging Initiative was explored. This evidence concerns the gene NEFL and early-onset autosomal dominant Alzheimer disease.